First Time Loading...
B

Betta Pharmaceuticals Co Ltd
SZSE:300558

Watchlist Manager
Betta Pharmaceuticals Co Ltd
SZSE:300558
Watchlist
Price: 42.84 CNY -3.08% Market Closed
Updated: May 11, 2024
Section:
 

Relative Value

The Relative Value of one Betta Pharmaceuticals Co Ltd stock under the Base Case scenario is 35.47 CNY. Compared to the current market price of 42.84 CNY, Betta Pharmaceuticals Co Ltd is Overvalued by 17%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
35.47 CNY
Overvaluation 17%
Relative Value
Price
B
Worst Case
Base Case
Best Case

Valuation Multiples

6.7
P/S
P/S
Price to Sales
6.7
vs History
93
vs Industry
21
Median 3Y
9.6
Median 5Y
12.1
Industry
2.5
Forward
5
More Details
45.4
P/E
P/E
Price to Earnings
45.4
vs History
92
vs Industry
9
Median 3Y
73.7
Median 5Y
88
Industry
23.4
Forward
36.3
More Details
17.5
P/OCF
P/OCF
Price to OCF
17.5
vs History
93
vs Industry
25
Median 3Y
52.6
Median 5Y
54.5
Industry
17.9
More Details
45.5
P/FCFE
P/FCFE
Price to FCFE
45.5
vs History
28
vs Industry
13
Median 3Y
23.3
Median 5Y
15.2
Industry
24.1
More Details
3.4
P/B
P/B
Price to Book Value
3.4
vs History
92
vs Industry
23
Median 3Y
4.8
Median 5Y
7.1
Industry
2.1
More Details
7.3
EV/S
EV/S
Enterprise Value to Sales
7.3
vs History
93
vs Industry
18
Median 3Y
9.9
Median 5Y
12.3
Industry
2.6
Forward
5.3
More Details
8.8
EV/GP
EV/GP
Enterprise Value to Gross Profit
8.8
vs History
90
vs Industry
25
Median 3Y
11.3
Median 5Y
13.2
Industry
5.2
More Details
45.8
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
45.8
vs History
95
vs Industry
7
Median 3Y
84.7
Median 5Y
89.9
Industry
13.9
Forward
21.9
More Details
45.8
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
45.8
vs History
95
vs Industry
8
Median 3Y
84.7
Median 5Y
89.9
Industry
17.5
Forward
34
More Details
18.9
EV/OCF
EV/OCF
Enterprise Value to OCF
18.9
vs History
93
vs Industry
25
Median 3Y
50.5
Median 5Y
52.8
Industry
16.4
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-83.3
Median 5Y
-83.3
Industry
18.1
More Details
2.5
EV/IC
EV/IC
Enterprise Value to IC
2.5
vs History
92
vs Industry
31
Median 3Y
3.5
Median 5Y
5.3
Industry
1.9
More Details

Multiples Across Competitors

Competitors Multiples
Betta Pharmaceuticals Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Betta Pharmaceuticals Co Ltd
SZSE:300558
17.9B CNY 6.7 45.4 45.8 45.8
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
722.3B USD 20.1 117.7 57.6 65.6
DK
Novo Nordisk A/S
CSE:NOVO B
3.9T DKK 16.1 44.1 32.9 36.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
360.8B USD 4.2 9.4 11.6 15.1
US
Merck & Co Inc
NYSE:MRK
329.4B USD 5.4 142.8 35.6 58.1
UK
AstraZeneca PLC
LSE:AZN
191.8B GBP 5 37.9 174.6 278.6
CH
Novartis AG
SIX:NOVN
180.6B CHF 3.4 11.4 8.7 12.7
CH
Roche Holding AG
SIX:ROG
179.5B CHF 3.1 15.6 8.9 10.5
US
Pfizer Inc
NYSE:PFE
158.1B USD 2.9 -511.8 12.7 20.2
P/E Multiple
Earnings Growth
CN
B
Betta Pharmaceuticals Co Ltd
SZSE:300558
Average P/E: 53
45.4
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
117.7
346%
DK
Novo Nordisk A/S
CSE:NOVO B
44.1
84%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
US
Johnson & Johnson
NYSE:JNJ
9.4
-20%
US
Merck & Co Inc
NYSE:MRK
142.8
7 454%
UK
AstraZeneca PLC
LSE:AZN
37.9
168%
CH
Novartis AG
SIX:NOVN
11.4
15%
CH
Roche Holding AG
SIX:ROG
15.6
26%
US
Pfizer Inc
NYSE:PFE
Negative Multiple: -511.8
680%

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 136,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.